The state of Iowa has designated $2 million in federal CARES Act funding to support university research and development of a nanovaccine to protect against COVID-19 infections. Researchers at Iowa State University and the University of Iowa, led by Balaji Narasimhan, director of the Nanovaccine Institute, an Anson Marston Distinguished Professor in Engineering and the Vlasta Klima Balloun Faculty Chair in Chemical and Biological Engineering, will work together on a nanovaccine they expect will be needle-free, single-dose and won’t require refrigeration.
Cheryl Khoo says Iowa State provides new ideas and a diverse community. While she was working as a quality control technician at BASF, Cheryl Khoo was given a major improvement project that helped her realize her interests spanned beyond chemical engineering. She says the project required her to track all non-conformance aspects of production to …Continue reading “Industrial engineering graduate student learns about continuous improvement”
Balaji Narasimhan, Vlasta Klima Balloun Professor of Chemical Engineering, discussed the potential of nanovaccines at the annual meeting of the American Chemical Society in Dallas, Texas, held March 16-20. Nanovaccines, which embed proteins from disease-causing organisms into tiny, polymer spheres five hundred times smaller than the width of a human hair, can be designed to target any …Continue reading “Room-temperature vaccine could be boon to developing countries”
Iowa State University researchers think developing nanovaccines using a “systems” approach can revolutionize the prevention and treatment of diseases. Just think, since 1980 the world has seen more new diseases than medical science knew before 1980, said Balaji Narasimhan, Iowa State’s Vlasta Klima Balloun Professor of Chemical and Biological Engineering and leader of a new project designed …Continue reading “Iowa State researchers setting up ‘dream team’ to research, develop nanovaccines”
In the past few months, College of Engineering researchers on three projects—one on novel nanovaccines, one on new wind turbine structures, and another on energy and transportation infrastructure planning—have reached key milestones in their research. Here are some highlights: Making one-dose, needle-free nanovaccines for infectious diseases Can you imagine a world where diseases such as …Continue reading “Research updates”